Conference Coverage

Higher buprenorphine doses help OUD patients stay in treatment


 

AT APA 2023

Medication is the ‘star’

In an interview, addiction specialist Dave Cundiff, MD, MPH, of Ilwaco, Wash., praised the study and agreed with its conclusions about the value of high doses of buprenorphine.

“They’re confirming what the science has already shown, but the world does not accept,” he said, adding that “for opioid use disorder, the medication is the star of the show, although counseling is a necessary adjunct for some patients.”

Dr. Cundiff said he’s coauthored a pending review article that finds that studies support higher doses of buprenorphine.

MaryAnne Murray, DNP, EdD, MBA, a psychiatric mental health nurse practitioner who’s married to Dr. Cundiff, said in an interview that the evolution of the opioid epidemic supports the use of higher doses. “The old way we used to do with heroin users was to wait until they’re in moderate withdrawal, and then start up buprenorphine, usually slowly. With fentanyl, it takes longer, and the wait is often less bearable – unbearable for many people.”

Transitions Buprenorphine Clinic of Sacramento funded the study. The authors, Dr. Cundiff, and Dr. Murray have no disclosures.

Pages

Recommended Reading

New insight into the growing problem of gaming disorder
MDedge Psychiatry
Should you recommend e-cigs to help patients quit smoking?
MDedge Psychiatry
Why is buprenorphine use flatlining?
MDedge Psychiatry
Survey reveals room for improvement in teen substance use screening
MDedge Psychiatry
Young men at highest schizophrenia risk from cannabis abuse
MDedge Psychiatry
FDA moves to curb misuse of ADHD meds
MDedge Psychiatry
Overdose deaths mark another record year, but experts hopeful
MDedge Psychiatry
Serious complications due to ‘huffing’
MDedge Psychiatry
FDA approves buprenorphine injection for opioid use disorder
MDedge Psychiatry
Buprenorphine update: Looser rules and a helpful injectable
MDedge Psychiatry